Novonesis (Novozymes) B
NSISBC
Clasificación en acciones
#1144
Established in January 2024 through the amalgamation of Novozymes A/S and Chr.... Established in January 2024 through the amalgamation of Novozymes A/S and Chr. Hansen, Novonesis now stands as a prominent global leader in biosolutions. The firm's activities encompass the worldwide development and commercialization of industrial enzymes, diverse microorganisms, and vital biopharmaceutical ingredients. Distinctively, its Class B shares are listed independently and actively traded on various European exchanges.
Precio por acción
$71.06
Capitalización bursátil
$19.75B
Cambio (1 día)
1.36%
Cambio (1 año)
12.07%
País
DK
Comercio Novonesis (Novozymes) B (NSISBC)
Categoría
Basic Materials
Ganancias de Novonesis (Novozymes) B (NSISBC)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Novonesis (Novozymes) B, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Novonesis (Novozymes) B desde 2019 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2025 | $871.87M | 100.88% |
| 2024 | $434.01M | -25.01% |
| 2023 | $578.78M | -11.74% |
| 2022 | $655.76M | 9.28% |
| 2021 | $600.08M | 3.82% |
| 2020 | $577.98M | 1.37% |
| 2019 | $570.15M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $9.50B | - |
GB
|
|
| - | - |
FR
|
|
| $3.49B | - |
US
|
|
| $2.63B | - |
US
|
|
| $-82.10M | - |
US
|
